BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17097943)

  • 1. Calcineurin inhibitors affect circulating regulatory T cells in stable renal transplant recipients.
    San Segundo D; Ruiz JC; Fernández-Fresnedo G; Izquierdo M; Gómez-Alamillo C; Cacho E; Benito MJ; Rodrigo E; Palomar R; López-Hoyos M; Arias M
    Transplant Proc; 2006 Oct; 38(8):2391-3. PubMed ID: 17097943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients.
    Segundo DS; Ruiz JC; Izquierdo M; Fernández-Fresnedo G; Gómez-Alamillo C; Merino R; Benito MJ; Cacho E; Rodrigo E; Palomar R; López-Hoyos M; Arias M
    Transplantation; 2006 Aug; 82(4):550-7. PubMed ID: 16926600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced numbers of blood natural regulatory T cells in stable liver transplant recipients with high levels of calcineurin inhibitors.
    San Segundo D; Fábrega E; López-Hoyos M; Pons F
    Transplant Proc; 2007 Sep; 39(7):2290-2. PubMed ID: 17889166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus did not affect CD4(+)CD25(high) forkhead box p3(+)T cells of peripheral blood in renal transplant recipients.
    Chu ZQ; Ji Q
    Transplant Proc; 2013; 45(1):153-6. PubMed ID: 23375290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of immuosuppressive therapy on the development of CD4+CD25+ T cells after renal transplantation.
    Korczak-Kowalska G; Wierzbicki P; Bocian K; Klosowska D; Niemczyk M; Wyzgal J; Korecka A; Durlik M; Chmura A; Paczek L; Górski A
    Transplant Proc; 2007 Nov; 39(9):2721-3. PubMed ID: 18021968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
    Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients.
    Balfour IC; Srun SW; Wood EG; Belsha CW; Marshall DL; Ferdman BR
    J Heart Lung Transplant; 2006 May; 25(5):518-22. PubMed ID: 16678029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CNI induced Th17/Treg imbalance and susceptibility to renal dysfunction in renal transplantation.
    Li Y; Shi Y; Huang Z; Bai Y; Niu Q; Cai B; Wang L; Feng W
    Int Immunopharmacol; 2011 Dec; 11(12):2033-8. PubMed ID: 21911083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression.
    Kandaswamy R; Humar A; Casingal V; Gillingham KJ; Ibrahim H; Matas AJ
    Transplantation; 2007 Mar; 83(6):722-6. PubMed ID: 17414704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory T cells in renal transplantation and modulation by immunosuppression.
    López-Hoyos M; Segundo DS; Fernández-Fresnedo G; Marín MJ; González-Martín V; Arias M
    Transplantation; 2009 Aug; 88(3 Suppl):S31-9. PubMed ID: 19667959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
    Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative analysis of regulatory T cells in kidney graft recipients: a relationship with calcineurin inhibitor level.
    Calvo-Turrubiartes M; Romano-Moreno S; García-Hernández M; Chevaile-Ramos JA; Layseca-Espinosa E; González-Amaro R; Portales-Pérez D
    Transpl Immunol; 2009 May; 21(1):43-9. PubMed ID: 19233271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion from calcineurin inhibitors to sirolimus in kidney transplant patients reduces the urinary transforming growth factor-beta1 concentration.
    Saurina A; Campistol JM; Lario S; Oppenheimer F; Diekmann F
    Transplant Proc; 2007 Sep; 39(7):2138-41. PubMed ID: 17889117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation of calcineurin inhibitors treatment allows the development of FOXP3+ regulatory T-cells in patients after kidney transplantation.
    van de Wetering J; Koumoutsakos P; Peeters A; van der Mast BJ; de Kuiper P; IJzermans JN; Weimar W; Baan CC
    Clin Transplant; 2011; 25(1):40-6. PubMed ID: 20636406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcineurin inhibitor-free immunosuppression in kidney transplantation.
    Guerra G; Srinivas TR; Meier-Kriesche HU
    Transpl Int; 2007 Oct; 20(10):813-27. PubMed ID: 17645419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
    Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure.
    Carmellini M; Collini A; Ruggieri G; Garosi G; Bernini M
    Transplant Proc; 2008; 40(6):1858-61. PubMed ID: 18675070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction.
    Krüger B; Fischereder M; Jauch KW; Graeb C; Hoffmann U; Böger CA; Banas B; Obed A; Schlitt HJ; Krämer BK
    Transplant Proc; 2007 Mar; 39(2):518-21. PubMed ID: 17362772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.